Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wislez, M.
Right arrow Articles by Cadranel, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wislez, M.
Right arrow Articles by Cadranel, J.
(Chest. 2003;123:1868-1877.)
© 2003 American College of Chest Physicians

Clinical Characteristics of Pneumonic-Type Adenocarcinoma of the Lung*

Marie Wislez, MD; Marie-Ange Massiani, MD; Bernard Milleron, MD, FCCP; Abdelkader Souidi, MD; Marie-France Carette, MD; Martine Antoine, MD and Jacques Cadranel, MD, PhD

* From Laboratoire de Biologie Cellulaire et d’Immunopathologie Pulmonaire (Drs. Wislez, Milleron, and Cadranel), UPRES EA 3493, Université Paris VI, UFR Saint-Antoine, Paris; and Services de Pneumologie et de Réanimation Respiratoire (Dr. Massiani and Souidi), et de Radiologie (Dr. Carette), et d’Anatomie Pathologique (Dr. Antoine), AP-HP, Hôpital Tenon, Paris, France.

Correspondence to: Jacques Cadranel, MD, PhD, Service de Pneumologie et de Réanimation Respiratoire, Hôpital Tenon, 4 rue de la chine, 75020 Paris, France; e-mail: jacques.cadranel{at}tnn.ap-hop-paris.fr

Purpose: To analyze diagnostic approaches, survival predictors, and treatment efficacy in pneumonic-type adenocarcinoma (P-ADC).

Patients and methods: Fifty-two patients with P-ADC diagnosed between January 1986 and December 2000 were studied. P-ADC was defined as histologically or cytologically proven pulmonary adenocarcinoma with a pneumonia-like consolidation, in a patient with no prior diagnosis of thoracic or extrathoracic adenocarcinoma.

Results: Sixty percent of the patients were men (n = 31), and 65% (n = 34) were current or former smokers. Mean (± SD) age at diagnosis was 66 ± 1.4 years. P-ADC was diagnosed by routine chest radiography in 17% of cases (n = 9). Bronchorrhea was present in 31% of cases (n = 16), and crepitant rales in 58% (n = 30). The primary tumor appeared as consolidations, which could not be assessed and were thus classified Tx, in 83% of the patients (n = 43). Ten percent of the patients (n = 5) had a satellite tumor within the lobe containing the primary tumor (T4), and 63% (n = 33) had a satellite tumor in another lobe (M1). Extrathoracic metastases were present in 5% of cases (n = 3). Bronchial biopsy, transbronchial biopsy, bronchial aspiration, and BAL were positive in 21%, 80%, 44%, and 66% of cases, respectively. The median survival time after diagnosis was 10.5 months (range, 1 to 150 months). The outcome of patients treated by lobectomy or bilobectomy was significantly better than that of patients treated with pneumonectomy, chemotherapy, or best supportive care (p < 0.01). Bronchorrhea and crepitant rales were independent predictors of shorter survival when the treatment modality (surgery vs no surgery) was not entered as a risk factor.

Conclusions: P-ADC is characterized by aerogenous propagation, as emphasized by the results of multivariate analysis showing that bronchorrhea and crepitant rales were the only two independent factors of shorter survival. Surgery remains the most effective treatment in P-ADC, especially when lobectomy is feasible. As CT is not sensitive enough to detect multifocal lesions, new tools are required to evaluate pulmonary involvement and thereby to refine the surgical strategy.

Key Words: adenocarcinoma • aerogenous progression • consolidation




This article has been cited by other articles:


Home page
Eur Respir JHome page
F. Suau, V. Cottin, F. Archer, S. Croze, J. Chastang, G. Cordier, F. Thivolet-Bejui, J-F. Mornex, and C. Leroux
Telomerase activation in a model of lung adenocarcinoma
Eur. Respir. J., June 1, 2006; 27(6): 1175 - 1182.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.